Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
暂无分享,去创建一个
C. Limatola | E. Novellino | A. Coluccia | A. Brancale | E. Crespan | G. Maga | R. Silvestri | G. La Regina | R. Badia | J. Esté | M. Catalano | Domiziana Masci | R. Cirilli | Eva Riveira-Muñoz | A. Brambilla | Valeria Famiglini | F. Formica | E. Riveira-Muñoz
[1] Mar Alvarez,et al. Viral reverse transcriptases. , 2017, Virus research.
[2] Peng Zhan,et al. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. , 2016, Journal of medicinal chemistry.
[3] Peng Zhan,et al. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. , 2016, Journal of medicinal chemistry.
[4] R. Silvestri,et al. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors , 2016, Molecules.
[5] G. Giannini,et al. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent. , 2015, Antiviral research.
[6] E. Novellino,et al. Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2014, Journal of Medicinal Chemistry.
[7] E. Novellino,et al. New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2014, European journal of medicinal chemistry.
[8] D. Broadhurst,et al. Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS , 2014, Retrovirology.
[9] L. Lisi,et al. Antiretroviral agents increase NO production in gp120/IFNγ-stimulated cultures of rat microglia via an arginase-dependent mechanism , 2014, Journal of Neuroimmunology.
[10] Daniel R Roe,et al. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.
[11] Liping Wang,et al. Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2012, Journal of medicinal chemistry.
[12] E. Novellino,et al. New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2012, Journal of medicinal chemistry.
[13] Margaret T May,et al. Life expectancy of HIV-positive adults: a review. , 2011, Sexual health.
[14] Jialin C. Zheng,et al. Glutaminase Dysregulation in HIV-1-Infected Human Microglia Mediates Neurotoxicity: Relevant to HIV-1-Associated Neurocognitive Disorders , 2011, The Journal of Neuroscience.
[15] E. Novellino,et al. Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at the indole-2-carboxamide , 2011 .
[16] F. Maldarelli,et al. Clinical Management of HIV Drug Resistance , 2011, Viruses.
[17] E. Novellino,et al. Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide. , 2011, Journal of medicinal chemistry.
[18] M. Harris-White,et al. Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction , 2010, Immunologic research.
[19] A. Coluccia,et al. Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase Inhibitors , 2010, Antiviral chemistry & chemotherapy.
[20] Dan J Stein,et al. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review , 2010, Journal of NeuroVirology.
[21] Xiaohong Liu,et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. , 2010, Journal of medicinal chemistry.
[22] B. Fredholm,et al. Adenosine A1 Receptors and Microglial Cells Mediate CX3CL1-Induced Protection of Hippocampal Neurons Against Glu-Induced Death , 2010, Neuropsychopharmacology.
[23] E. Novellino,et al. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. , 2009, Journal of medicinal chemistry.
[24] Marwen Naïm,et al. Molecular dynamics-solvated interaction energy studies of protein-protein interactions: the MP1-p14 scaffolding complex. , 2008, Journal of molecular biology.
[25] C. Limatola,et al. Activity of Adenosine Receptors Type 1 Is Required for CX3CL1-Mediated Neuroprotection and Neuromodulation in Hippocampal Neurons1 , 2008, The Journal of Immunology.
[26] G. McGaughey,et al. Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs). , 2008, Bioorganic & medicinal chemistry letters.
[27] Thomas Stützle,et al. An ant colony optimization approach to flexible protein–ligand docking , 2007, Swarm Intelligence.
[28] Imran Siddiqi,et al. Solvated Interaction Energy (SIE) for Scoring Protein-Ligand Binding Affinities, 1. Exploring the Parameter Space , 2007, J. Chem. Inf. Model..
[29] J. Brenchley,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.
[30] P. Kollman,et al. Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.
[31] N. Brabers,et al. Role of the pro‐inflammatory cytokines TNF‐α and IL‐1β in HIV‐associated dementia , 2006, European journal of clinical investigation.
[32] A. Bergamini,et al. Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. , 2006, Journal of medicinal chemistry.
[33] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[34] H. Pajouhesh,et al. Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.
[35] P. Simmonds,et al. Influence of HAART on HIV-related CNS disease and neuroinflammation. , 2005, Journal of neuropathology and experimental neurology.
[36] K. Hertogs,et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. , 2005, Journal of medicinal chemistry.
[37] A. Coluccia,et al. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives. , 2005, Journal of medicinal chemistry.
[38] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[39] R. Silvestri,et al. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. , 2004, Journal of medicinal chemistry.
[40] S. Croul,et al. Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy. , 2004, The American journal of pathology.
[41] Silvio Massa,et al. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. , 2003, Journal of medicinal chemistry.
[42] H. Berman,et al. Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank , 2022 .
[43] J. Verhoef,et al. Monocyte infiltration is highly associated with loss of the tight junction protein zonula occludens in HIV‐1‐associated dementia , 2000, Neuropathology and applied neurobiology.
[44] U Hübscher,et al. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. , 1997, Journal of molecular biology.
[45] J. Glass,et al. Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry , 1997, Journal of Neuroimmunology.
[46] A. D. Clark,et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.
[47] M. Ciotti,et al. Development of a method for measuring cell number: application to CNS primary neuronal cultures. , 1994, Cytometry.
[48] S. Hirono,et al. Comparison of Reliability of log P Values for Drugs Calculated by Several Methods , 1994 .
[49] S. Hirono,et al. Simple Method of Calculating Octanol/Water Partition Coefficient. , 1992 .
[50] A. Coluccia,et al. An in-silico approach aimed to clarify the role of Y181C and K103N HIV-1 reverse transcriptase mutations versus Indole Aryl Sulphones. , 2016, Journal of molecular graphics & modelling.
[51] E. Clercq. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). , 2013 .
[52] T. Hawkins. Understanding and managing the adverse effects of antiretroviral therapy. , 2010, Antiviral research.
[53] T. Cihlar,et al. Current status and challenges of antiretroviral research and therapy. , 2010, Antiviral research.
[54] B. Brew,et al. Involvement of quinolinic acid in aids dementia complex , 2009, Neurotoxicity Research.
[55] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[56] H. Nottet. Interactions between macrophages and brain microvascular endothelial cells: role in pathogenesis of HIV-1 infection and blood - brain barrier function. , 1999, Journal of neurovirology.